Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus

British Journal of Rheumatology

Volumn 36, Issue 2, 1997, Pages 190-193

  Gilad, R ^a   Lampl, Y ^a   Eshel, Y ^b   Barak, V ^c   Sarova Pinhas, I ^b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cerebral lupus; Interleukin; Stroke; Systemic lupus

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; HEART DISEASE; HUMAN; MALE; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030859141     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.2.190     Document Type: Article

References (22)

1. Bernstein RM. Cerebral lupus: a peep into Pandora's box [Editorial]. J Rheumatol 1982;9:817-8.
2. Hughes GRV. Connective tissue diseases, 2nd edn. Oxford: Blackwell Scientific Publications, 1979.
3. Hirohata S, Hinose S, Miyamoto T. Cerebrospinal fluid IgM, IgA and IgG indexes in systemic lupus erythematosus: their use as estimates of central nervous system disease activity. Arch Intern Med 1985;145:1843-6.
4. Hirohata S, Miyamoto T. Increased intrathecal immunoglobulin synthesis of both kappa and lambda types in patients with systemic lupus erythematosus and central nervous system involvement. J Rheumatol 1986;13:715-21.
5. Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatrie manifestations of systemic lupus erythematosus. Am J Med 1981;70:240-6.
6. Bluestein HG, Woods VL Jr. Antineuronal antibodies in systemic lupus erythematosus. Arthritis Rheum 1982;25:773-8.
7. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli and thrombotic thrombocytopenic purpura. Ann Neurol 1988;23:380-6.
8. Harris EB, Ggavaru AE, Hughes GRV. Anti phospholipid antibodies. Clin Rheum Dis 1985;11:591-601.
9. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990;33:644-9.
10. Robin LA, Nelson DL. The soluble iriterleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990;113:619-27.
11. Rosen S. The multichain interleukin-2 receptor. J Am Med Assoc 1990;263:272-4.
12. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameters: lumbar puncture. Neurology 1993;43:625-7.
13. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977;37:385-90.
14. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Invest 1977;37:391-6.
15. Tohgi H, Takahashi S, Chiba R, Hirata Y. Clinical and neuroimaging analysis in 293 patients for the Tohoku Cerebellar Infarction Stroke Group. Stroke 1993;24:1697-701.
16. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield N F et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
17. Danieli MG, Paoletti P, Recchioni A, Gabrielli A, Danieli G. Serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and systemic idiopathic vasculitis. Scand J Rheumatol 1993;22:215-9.
18. ter Borg EJ, Horst G, Limburg PC et al. Changes in plasma levels of IL-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in SLE. Clin Exp Immunol 1990;82:21-6.
19. Wong KL, Wong RPO. Serum soluble interleukin-2 receptor in systemic lupus erythematosus: effects of disease activity and infections. Ann Rheum Dis 1991;50:706-9.
20. Campen DH, Horwitz DA, Quismorio FP Jr et al. Serum levels of soluble interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum 1988;31:1358-64.
21. Cowell BM, Beawer N, Clarli W. Elevated fibrinogen and plasma interleukin 6 in acute stroke. Neurology 1994;44(suppl. 2):289.
22. Mitsias P, Levine SR. Large vessel occlusive disease in systemic lupus erythematosus. Neurology 1994; 44:385-93.